By combining two existing therapies, researchers at the Royal Marsden NHS Foundation Trust in London have found that they have been able to stop or even reverse the progression of advanced melanoma in half of patients. The two therapies, ipilmumab and nivolumab, were tested on patients over the course of five years. The findings were published online ahead of print in the New England Journal of Medicine (Sept. 28, 2019).
Combination of Three Therapies May Slow Progression of Advanced Melanoma
Three therapies, when used in combination, may slow advanced melanoma, according to a new study led by researchers at UCLA. The study, published online ahead of print in the journal Nature Medicine (June 6, 2019) showed that the combination of dabrafenib, trametinib, and pembrolizaumab can slow the growth of advanced melanoma cancer cells.
History of smoking decreases survival rate in melanoma patients
Skin cancer patients with a history of smoking have a significantly lower survival rate than skin cancer patients who do not smoke. Smoking cigarettes decreases survival rate in melanoma patients by 40 per cent according to a new study published by the medical journal Cancer Research (Feb. 17, 2019).
Melanoma survival rate in US higher in states with more diagnosed cases
Patients in the United States who live in a state with a higher incidence of melanoma are more likely to survive the disease. Conversely, Americans who live in a state with a lower incidence of melanoma are less likely to survive the disease. Researchers believe that this seeming contradiction might be a result of better detection in more well-funded regions leading to better outcomes.
HealthMinute.TV 